30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
What is known Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Cerebrospinal fluid (CSF) levels of Abeta peptide 1-42 (Abeta 42), tau, and phosphorylated tau (ptau) are potential biomarkers of Alzheimer disease. 4 key findings →
Design: longitudinal study Participants: 49 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Online literature databases and trial registers, previous systematic reviews and leading journals were searched for relevant randomised controlled trials. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Vitamin C plays a role in neuronal differentiation, maturation, myelin formation and modulation of the cholinergic, catecholinergic, and glutaminergic systems. 4 key findings →
Design: case-control study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The Mini-Mental State Examination (MMSE) is recommended to test for cognitive impairment and to monitor medication response. 4 key findings →
Design: randomized controlled trial Participants: 7,073 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We sought to assess risk of COVID-19 among front-line health-care workers compared with the general community and the effect of personal protective equipment (PPE) on risk. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
In univariate analysis, all 29 adiposity and metabolic measures assessed were associated with ' g ' at P < 0.05. 5 key findings →
Participants: 8,769 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Characterizing subtle cognitive changes in preclinical Alzheimer's disease (AD) is difficult using traditional neuropsychological assessments. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Combinations of plasma and digital cognitive markers show promise for scalable diagnosis and prognosis of ADRD. 1 key finding →
Participants: 49 Evidence: low
Full summary, score breakdown and related studies → Original source
Increased variability in monthly RT may reflect subtle EF deficits and provide unique information about short-term cognitive decline in preclinical Alzheimer's disease. 1 key finding →
Design: cross-sectional Participants: 109 Evidence: low
Full summary, score breakdown and related studies → Original source
Further longitudinal exploration of lifespace is required to develop an understanding of the nature of lifespace of older community-dwelling people, and its relationship with health, mobility and well-being outcomes. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The TabCAT-EXAMINER is a tablet-based executive functioning battery developed for observational research and clinical trials. 4 key findings →
Design: cross-sectional Participants: 342 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our findings suggest that the tablet-based SCST may be another option to traditional paper-and-pencil neuropsychological tests, especially in situations where time and space are relatively limited, and neuropsychological testing specialists are not available. 4 key findings →
Participants: 197 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Technological developments provide solutions to alleviate the tremendous impact on the health and autonomy due to the impact of dementia on navigation abilities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
BackgroundCardiovascular health (CVH) is a modifiable risk factor for Alzheimer's disease (AD). 3 key findings →
Participants: 1,198 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A growing body of evidence suggests that the plasma concentration of the neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer's disease (AD). 4 key findings →
Participants: 25 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The role of atrial fibrillation in cognitive impairment and dementia, independent of stroke, is uncertain. 4 key findings →
Design: post-hoc analysis Participants: 31,506 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Baseline data available from 59 patients enrolled in the PSYCLOPS (PSychosis and CLOzapine in PD Study) trial included age, age at onset of PD, duration of PD and psychosis, character of psychosis, medications, living setting, and scores for Mini-Mental State Examination (MMSE), Unified Parkinson's Disease Rating Scale, Hoehn and Yahr Scale, and Clinical Global Impression Scale. 4 key findings →
Design: longitudinal study Participants: 59 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The effectiveness and safety of yokukansan (TJ-54), a traditional Japanese medicine (kampo) for the treatment of the behavioural and psychological symptoms of dementia (BPSD), were evaluated in 106 patients diagnosed as having Alzheimer's disease (AD) (including mixed-type dementia) or dementia with Lewy bodies. 4 key findings →
Participants: 106 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Ginseng is one of the most popular herbs worldwide. 4 key findings →
Participants: 15 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This intent-to-treat (ITT) analysis was performed to provide a realistic image of the efficacy that could be expected after 26 weeks treatment with a 120-mg dose (40 mg t.i.d.) of EGb 761 (EGb). 4 key findings →
Participants: 309 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
CERAD was funded by the National Institute on Aging with a mandate to standardize assessment in Alzheimer's disease. 5 key findings →
Design: longitudinal study Participants: 1,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
David Moher and colleagues introduce PRISMA. 1 key finding →
Full summary, score breakdown and related studies → Original source Free full text
Cochrane Reviews have recently started including the quantity I(2) to help readers assess the consistency of the results of studies in meta-analyses.
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events